SCHEDULE 13G/A: Baillie Gifford & Co Amends Moderna Stake, Disclosing 6.45% Beneficial Ownership

Baillie Gifford & Co has filed an Amendment No. 5 to Schedule 13G, disclosing its beneficial ownership of 6.45% of Moderna, Inc.'s Common Stock as of March 31, 2025.

Summary

• Baillie Gifford & Co, an investment adviser based in Scotland, has filed an Amendment No. 5 to Schedule 13G regarding its holdings in Moderna, Inc.
• As of March 31, 2025, Baillie Gifford & Co beneficially owns an aggregate of 24,948,558 shares of Moderna, Inc. Common Stock.
• This beneficial ownership represents 6.45% of the class of securities.
• The firm holds sole voting power over 23,662,282 shares and sole dispositive power over 24,948,558 shares.
• No shared voting or dispositive power is reported.
• The securities are held by Baillie Gifford & Co and/or its investment adviser subsidiaries on behalf of investment advisory clients, which may include investment companies, employee benefit plans, pension funds, or other institutional clients.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership by an institutional investor, providing no positive or negative sentiment regarding the issuer's performance or outlook.

Industry Context

This filing indicates continued significant institutional ownership in Moderna, a leading biotechnology company known for its mRNA technology, particularly in vaccines. Large institutional holdings like this are common for established public companies and reflect ongoing investment by major asset managers.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional holdings, which can influence market perception and liquidity.

Key Dates

Keywords

Moderna, Baillie Gifford, SEC filing, Schedule 13G, Common Stock, beneficial ownership, institutional investor, investment adviser, MRNA